Searching for Lyme borreliosis in Australia: results of a canine sentinel study

Peter J. Irwin1,2*, Ian D. Robertson2, Mark E. Westman3, Martine Perkins4 and Reinhard K. Straubinger5

Abstract

Background: Lyme borreliosis is a common tick-borne disease of the northern hemisphere that is caused by bacterial spirochaetes of the Borrelia burgdorferi (sensu lato) (Bbsl) complex. To date, there has been no convincing evidence for locally-acquired Lyme borreliosis on the Australian continent and there is currently a national debate concerning the nature and distributions of zoonotic tick-transmitted infectious disease in Australia. In studies conducted in Europe and the United States, dogs have been used as sentinels for tick-associated illness in people since they readily contact ticks that may harbour zoonotic pathogens. Applying this principle, we used a combination of serological assays to test dogs living in tick ‘hot spots’ and exposed to the Australian paralysis tick, Ixodes holocyclus, for evidence of exposure to B. burgdorferi (s.l.) antigens and other vector-borne pathogens.

Results: Altogether, 555 dogs from four demographic groups were recruited into this study. One dog had evidence of exposure to Anaplasma spp. but no other dog was positive in screening tests. A total of 122 dogs (22.0%) had a kinetic ELISA (KELA) unit value > 100, and one dog with a high titre (399.9 KELA units) had been vaccinated against B. burgdorferi (sensu stricto) before travelling to Australia. Older dogs and those with a history of tick paralysis were significantly more likely to have a KELA unit value > 100. Line immunoassay analysis revealed moderate-to-weak (equivocal) bands in 27 (4.9%) dogs.

Conclusions: Except for a single dog presumed to have been exposed to Anaplasma platys, infection with Anaplasma spp. B. burgdorferi (s.l.), Ehrlichia spp., and Dirofilaria immitis, was not detected in the cohort of Australian dogs evaluated in this study. These results provide further evidence that Lyme borreliosis does not exist in Australia but that cross-reacting antibodies (false positive results) are common and may be caused by the transmission of other tick-associated organisms.

Keywords: Lyme borreliosis, Borrelia burgdorferi (s.l.), Anaplasma, Ehrlichia, Ixodes, Ticks, Vector-borne disease, Serology, Canine sentinel, Australia

Background

Animals are often the first to come in contact with microbes, contaminants, and pollutants that can cause illness in people and the development of clinical signs in these species can provide early warning for potential threats to human health. Multiple species of wild and domesticated animals have been utilised as sentinels of environmental hazards, including infectious diseases, and serosurveys of dogs have been widely conducted in North America and Europe as an adjunct to the surveillance of human Lyme borreliosis (LB), commonly termed Lyme disease (LD) [1–5].

Dogs are particularly effective sentinels for vector-borne diseases such as LB since their inquisitive behaviour off lead takes them into the long grass and shrub land where they have the potential to come into contact with questing ticks that harbour pathogens. It has been demonstrated that the prevalence of antibodies to Borrelia burgdorferi (s.l.) (Bbsl), the aetiological agents of LB, in endemic areas is significantly greater in dogs than in people [6]. Seropositivity to the LB agent was 0.4–25% in dogs tested in south eastern and mid-Atlantic regions of the USA [7], 8% in dogs in Maine, USA [2], 1.9–10.3% in Germany [8] and 17–18% amongst pet and hunting dogs in The Netherlands [1]. Serosurveys are, however, not without limitations and despite the high sensitivity and specificity of commercially available diagnostic tests, caution is advised when interpreting results, especially from convenience samples in low prevalence populations. Additionally, infection by Bbsl results in a...
lower incidence of clinical illness in dogs than it does in people [9]. It has been concluded that canine seroprevalence to Bbsl greater than 5% was a sensitive but non-specific marker of human risk, whereas seroprevalence less than 1% was associated with minimal risk of human infection [10].

In Australia, the diagnosis of LB and a so-called ‘Lyme disease-like syndrome’ has been the subject of much debate, recently resulting in a parliamentary hearing, a Senate enquiry, intense media interest, and three published reviews [11–14]. To date, except for rickettsiosis and coxiellosis, there is no convincing evidence for locally-acquired tick-borne infectious diseases of humans in Australia. Indeed, none of the recognised tick species (the ‘ricinus’ complex of Ixodes) responsible for vectoring LB and associated pathogens in other parts of the world occurs in Australia, and in one experimental study, it was concluded that Australia does not appear to have a competent vector of Bbsl [15]. Current medical opinion regarding positive results of screening antibody tests to Bbsl, and other tick-borne pathogens such as Anaplasma spp., Ehrlichia spp. and Babesia spp. in people with no overseas travel is that these most likely represent false positive serological test results [13].

There has been one previous survey for LB-specific antibodies in dogs in Australia, conducted in Brisbane, Queensland over twenty years ago [16]. Although approximately 40% of these dogs had a history of a tick bite, all serum samples were negative. Since that time recombinant purified antigens and peptides derived from the bacteria, including a Borrelia-specific lipoprotein VlsE (C6 peptide) have improved the sensitivity of detection of Bbsl tests while maintaining specificity in both screening assays and immunoblots. We hypothesised that dogs living within the geographical regions that coincide with the majority of the Lyme disease-like reports in humans (coastal NSW) would offer the greatest probability of detecting antibodies if LB was endemic within the tick populations within those regions. This cross-sectional canine serosurvey was conducted primarily to further the search for evidence of Bbsl and other vector-borne infections within Australia, selecting dogs considered most at risk should Bbsl be present i.e. targeted serosurveillance.

**Methods**

**Collection of samples**

Between April 2011 and December 2013 dogs were recruited into this cross-sectional study from four sources around Australia as described in Table 1 and Fig. 1. Each dog owner (Groups 1 & 2) completed a questionnaire

| Table 1 Group details |
|------------------------|
| Group | Number | Description and location |
| 1  | 381 | Dogs (multiple breeds) residing in the Northern Beaches local government area of Sydney, New South Wales (NSW) specifically within postcodes 2101–2108 and 2084 (Fig. 1). This densely populated area of NSW is highly enzootic for the Australian paralysis tick (Ixodes holocyclus). Numerous cases of tick paralysis in domestic animals are treated by veterinarians in this area each year and the emergency departments of three local hospitals (Mona Vale, Manly and Hornsby) collectively treated 1,131 tick bite presentations in humans between July 2014 and August 2016 (Dr Ben Taylor, Mona Vale Hospital, 2016 pers. com.). Dogs were recruited by advertisement through local veterinary hospitals and at the Pittwater (now Northern Beaches) Council’s annual event ‘Dog Day by the Bay’ (in 2012 and 2013) at the Rowland Reserve, Bayview. Dogs in this group represented a cohort considered highly likely to be exposed to I. holocyclus and therefore act as potential sentinels for human infections. |
| 2  | 60 | Dogs (multiple breeds) owned by and living with people with a variety of symptoms (e.g. headaches, joint and muscle pain, fatigue, sleeplessness, rash, memory loss, etc.) consistent with a ‘Lyme disease-like syndrome’, who had received a diagnosis of a tick-associated illness by a medical practitioner. Owners enrolled their dogs following advertisements by patient advocacy groups and by word of mouth. Dogs assigned to this group were located throughout Australia, but mostly in coastal NSW and Western Australia. Dogs in this group were chosen because of their close association with humans who had received a diagnosis and may, therefore, provide selective evidence for a sentinel status. |
| 3  | 84 | Dogs (foxhounds) resident at Northern Serums Pty Ltd, Lismore NSW, an APVMA-approved manufacturer of paralysis tick antiserum. Most (n = 79) of these dogs were bred within the facility, with five adult dogs sourced originally from elsewhere, i.e. Brisbane (n = 1) and Melbourne (n = 4). At this facility, approximately 400 unfed (questing) female I. holocyclus ticks collected from multiple locations in coastal NSW (Lismore North, Casino, Tabulam South, Macksville) and Queensland (Maleny, Atherton and Bauple Mountain) are attached to each dog annually and allowed to feed and engorge before removal. Blood is drawn regularly from these dogs for the manufacture of hyperimmune serum which is supplied commercially to veterinarians for the treatment of tick paralysis in domestic animals. Dogs in this group were chosen to specifically test the hypothesis that dogs bitten by I. holocyclus are sentinels for certain infections transmitted by this tick species. |
| 4  | 30 | Dogs (camp dogs; dingo crosses and other breeds) residing at two indigenous communities located on the Dampier Peninsula, north of Broome in the tropical Kimberley region of Western Australia. These dogs were sampled as part of routine health assessments and to determine the internal and external parasite load. In this area, there is a high prevalence of the brown dog tick (Rhipicephalus sanguineus) and minimal ectoparasite control. These dogs served as a control group since I. holocyclus does not occur in this location. |

**Total** 555

**Abbreviations:** APVMA Australian Pesticides and Veterinary Medicines Authority, NSW New South Wales
Fig. 1 Map showing the Northern Beaches area of Sydney, NSW, postcodes 2101–2108 and 2084, selected for sampling dogs in Group 1. (Map credit: voomMAPS.com)
soliciting information pertaining to the dog’s age, sex, breed, postcode of residence, history of ectoparasite (tick and flea) exposure (including tick paralysis), and travel history (local, interstate and overseas). Additionally, personal medical histories were provided by the owners of dogs in Group 2. Blood samples, collected by veterinarians, were transferred into EDTA-coated and serum (clot) tubes.

**Enzyme immunoassay testing**
Whole blood was screened for antibodies to *Bbsl*, *Anaplasma phagocytophilum*, *A. platys*, *Ehrlichia canis* and *E. chaffeensis*, and for *Dirofilaria immitis* antigen, using a rapid enzyme immunoassay (EIA) kit (SNAP® 4Dx and SNAP® 4Dx Plus, IDEXX Laboratories Inc., Westbrook, Maine, USA) according to the manufacturer’s instructions.

**PCR testing**
Positive samples from EIA test protocol were sent (on dry ice) for PCR analysis to the Vector Borne Disease Diagnostics Laboratory at North Carolina State University, Raleigh, USA [17].

**ELISA and Line immunoassay**
Following centrifugation and separation from blood cells, serum samples were stored at -20 °C at Murdoch University until batched and shipped (on ice) to the Ludwig-Maximilians-University in Munich, Germany, where they were analysed for *Bbsl*-specific antibodies, initially using a computerized kinetic ELISA (KELA, Sekisui Virotech GmbH, Rüsselsheim, Germany). Serum samples indicative for dogs which might have had contact with *Borrelia* organisms were defined as those with KELA unit value > 100 [18, 19] and two or more bands in the LIA to the following antigens: VlsE mix, OspA mix (31 kDa), DpbA mix, OspC mix (23 kDa), BmpA (39 kDa), p58, p83/100 [19].

**Statistical analysis**
Data were analysed using SPSS version 21. Categorical data were analysed with a Chi-square test for independence and odds ratios (OR) and their 95% confidence intervals (CI) calculated. For the continuous variable (age), an ANOVA was used to compare dogs with KELA units > 100 (equivocal to positive) and those < 100 (negative) after testing for homogeneity of variances and normality. An association between seropositivity and age, sex, ectoparasite exposure, history of tick paralysis and travel was evaluated with *P* < 0.050 considered significant.

**Results**
A total of 555 dogs were recruited into this study (Table 1). During initial screening by EIA, a single dog in Group 1 (a 5-year-old male Labrador living in Inglewood, NSW, 2101) returned a positive result to *Anaplasma* spp. antibodies. This dog had a history of tick attachment and tick paralysis, despite the owner reporting use of ectoparasiticides, and had not travelled away from home. Further analysis of a blood sample from this dog was negative on PCR for *Anaplasma* spp. DNA (data not shown). All other dogs tested were negative for *Bbsl*, *Anaplasma* spp. and *Ehrlichia* spp. antibodies, and for *D. immitis* antigen (Table 2).

**Table 2** Enzyme immunoassay serology test results

| Organism tested                  | Group 1 |          | Group 2 |          | Group 3 |          | Group 4 |          |
|----------------------------------|---------|----------|---------|----------|---------|----------|---------|----------|
|                                  | Pos     | Neg      | Pos     | Neg      | Pos     | Neg      | Pos     | Neg      |
| *Anaplasma platys/phagocytophilum* | 1       | 380      | 0       | 60       | 0       | 84       | 0       | 30       |
| *Ehrlichia canis/chaffeensis*     | 0       | 381      | 0       | 60       | 0       | 84       | 0       | 30       |
| *B. burgdorferi (s.l) (Bbsl) (C6)*| 0       | 381      | 0       | 60       | 0       | 84       | 0       | 30       |
| *Dirofilaria immitis*             | 0       | 381      | 0       | 60       | 0       | 84       | 0       | 30       |

**Table 3** Kinetic ELISA serology test results

| KELA value (units) | Number | Interpretation |
|--------------------|--------|----------------|
| 0–99.9             | 431    | negative       |
| 100–199.9          | 118    | positive       |
| 200–299.9          | 4      |                |
| > 300              | 1      |                |

Abbreviations: Neg negative, Pos positive
A total of 123 dogs (22.2%) were positive by ELISA (KELA units > 100; Table 3). One dog with a strong positive serological test result (KELA units = 399.4) had lived in the USA and information provided by the owner indicated this individual had been vaccinated against *B. burgdorferi* (s.s.) before travelling to Australia. As it was considered this titre was induced by vaccination, data from this dog were removed prior to further statistical analysis.

There was no sex predilection for antibodies with 24% of male dogs compared with 18% of females positive (*P* = 0.099) (Table 4). Slightly more dogs with a history of previous tick attachment (23.1%) were positive than those without a history of tick attachment (20.4%) and dogs that were positive were significantly older (6.5 years) than negative dogs (5.4 years) (*F*(1,513) = 6.7, *P* = 0.010). A higher percentage of dogs with a history of tick paralysis, implying prolonged attachment of *Ixodes holocyclus*, were positive (29.5%) compared with dogs without a history of tick paralysis (17.4%) (*P* = 0.002). The odds of positivity in dogs with tick paralysis was twice that of dogs without this specific history (Table 4). Neither a history of ectoparasiticide application (*χ*² = 0.871, *df* = 1, *P* = 0.351) nor previous exposure to fleas (*χ*² = 0.009, *df* = 1, *P* = 0.926) was significantly associated with seropositivity. Additionally, there was no significant association between the *Borrelia*-specific antibody levels (KELA units) and location as assessed by postcode (*χ*² = 1.186, *df* = 8, *P* = 0.997). A slightly higher percentage of dogs with a history of travel were seropositive (21.9%) compared with dogs without a history of travel (14.8%) (*P* = 0.064); the odds of positivity in travelling dogs was 1.6 (95% CI: 1.0–2.7) of dogs not travelling (Table 4).

There was a significant difference in seropositivity between the four groups (*χ*² = 17.094, *df* = 3, *P* = 0.001); the proportion of seropositive dogs using the ELISA was greatest in the group with the highest exposure to *I. holocyclus* ticks (Group 3 dogs used for antiserum production), with dogs in this group 2.7 times more likely to be positive (95% CI: 1.3–6.0) than dogs in Group 2 (Table 4).

Line immunoassay analysis revealed strong bands to recombinant OspA and DpbA antigens in the single vaccinated dog referred to above, and moderate-to-weak (equivocal) bands in a small number (n = 29; 4.9%) of other dogs. Three individuals (including the vaccinated dog) had three bands, one dog had two bands, and 25 dogs had a single positive band on LIA.

### Discussion

Canines have been identified in overseas studies to be useful sentinels for tick-transmitted zoonotic disease [20]. The main purpose of this study was to search for evidence of *B. burgdorferi* (s.l.), the causative agents of LB, and our results strongly suggest that these pathogens are not present in Australia. We hypothesised that if *B. burgdorferi* (s.l.), other related *Borrelia* species, or other zoonotic tick-associated pathogens were present in Australia, dogs exposed to vector ticks would develop antibodies that would be detected by one or more of the serological methods used in this study. Given that the identity of an Australian vector, if present, is unknown, we reasoned that for a locally transmitted tick-associated zoonotic infectious disease, or group of diseases, to become established in Australia, the tick(s) responsible would be relatively widely distributed and well known to attach to and feed on humans. Dogs with increased risk of exposure to *I. holocyclus* were therefore targeted, since this species parasitizes multiple vertebrate hosts, including humans, it belongs to the genus (*Ixodes*) which in the northern hemisphere is responsible for the transmission of LB-causing *Borrelia* organisms, *Anaplasma* spp. and *Babesia* spp. [21], and the geographical distribution of *I. holocyclus* appears to largely coincide with that of the LD-like cases reported in the scientific

| Group | Seropositive KELA units > 100 (n) | Seronegative KELA units < 100 (n) | Percent positive (95% CI) | OR (95% CI) |
|-------|----------------------------------|----------------------------------|---------------------------|-------------|
| 1     | 70                               | 310                              | 18.4 (14.7–22.7)          | 1.0 (0.5–2.0) |
| 2     | 11                               | 49                               | 18.3 (9.5–30.4)           | 1.0         |
| 3     | 32                               | 52                               | 38.1 (27.7–49.3)          | 2.7 (1.3–6.0) |
| 4     | 9                                | 21                               | 30.0 (14.7–49.4)          | 1.9 (0.7–5.3) |

Sex

| Sex   | Male   | Female | Percent positive (95% CI) | OR (95% CI) |
|-------|--------|--------|---------------------------|-------------|
|       | 67     | 42     | 24.0 (19.1–29.5)          | 1.4 (0.9–2.2) |

Tick history

| Tick history | Yes | No | Percent positive (95% CI) | OR (95% CI) |
|--------------|-----|----|---------------------------|-------------|
|               | 91  | 20 | 23.1 (19.0–27.6)          | 1.2 (0.7–2.0) |

Flea history

| Flea history | Yes | No | Percent positive (95% CI) | OR (95% CI) |
|--------------|-----|----|---------------------------|-------------|
|               | 46  | 24 | 18.9 (14.1–24.3)          | 1.0 (0.6–1.8) |

Ectoparasiticide use

| Ectoparasiticide use | Yes | No | Percent positive (95% CI) | OR (95% CI) |
|----------------------|-----|----|---------------------------|-------------|
|                      | 57  | 10 | 19.1 (14.8–24.0)          | 1.4 (0.7–2.9) |

Travel history

| Travel history | Yes | No | Percent positive (95% CI) | OR (95% CI) |
|---------------|-----|----|---------------------------|-------------|
|               | 50  | 10 | 21.9 (16.7–27.9)          | 1.6 (1.0–2.7) |

| Stayed at home | Total |
|----------------|-------|
| 122            | 432   |

*Data not available from every individual (some incomplete survey responses)

*One data point (vaccinated dog) has been removed from this analysis
Using three different serological methods, only one dog in the total cohort of 555 was assessed to have a reliably positive antibody response, and this dog, an 8-year-old female Labrador, was born in the USA, vaccinated against LB as part of a routine vaccination program in the USA, and travelled to Sydney, Australia in 2009, two years prior to being sampled for this study. Antibody levels induced by vaccination start to wane considerably within a few weeks after immunisation but may be detected for years [23]. This dog had the highest KELA value by a considerable margin (>150 KELA units) and three positive bands (very strong positive to OspA, with additional positive bands to DbpA-mix and a 58 kDa recombinant antigen) on LIA. The outer surface protein A (OspA) is a component of all approved LB vaccines. Another outer protein membrane protein, variable major protein-like sequence, expressed (VlsE) contains antigenically variable and invariable regions. Detection of antibody to the sixth invariable region of the VlsE protein (a peptide known as IR6 or the shorter synthetic version C6) has become a reliable serological marker for the diagnosis of LB and is incorporated into the rapid EIA used in this study. However, genes for the C6 peptide are only expressed during replication of Bbsl bacteria in the mammalian host, and this peptide is not incorporated into LB vaccines [24]. Unsurprisingly, therefore, the vaccinated dog described above was negative to the C6 antigen, and this result further indicated that no natural exposure to Bbsl had occurred in this individual.

Our data indicate that the prevalence of vector-borne infections, as determined by serological responses to a panel of antigens, was very low in the study groups. To some extent this result is unsurprising, since only A. platys, Babesia vogeli and canine haemoplasmas are reported to be transmitted to dogs by ticks in Australia, and each of these is vectored by the brown dog tick (R. sanguineus) [25]. Except for dogs in Group 4, the majority of individuals tested in the current study lived in southern and south-eastern regions of Australia where R. sanguineus is relatively uncommon; dogs in these temperate areas are much more likely to be bitten by I. holocyclus or the cattle tick Haemaphysalis longicornis, neither of which is known to vector the pathogens mentioned above [26]. Furthermore, Australia is currently considered by veterinary authorities to be free from A. phagocytophilum, E. canis (and E. chaffeensis), and members of the B. burgdorferi (s.l) complex [27]. The single positive result to Anaplasma spp. with the rapid EIA testing could have represented an antibody response to A. platys, A. phagocytophilum, or a false positive result.

One likely explanation that despite living in Sydney and returning a negative PCR result, this dog was at some previous time been bitten by R. sanguineus with the subsequent transmission of A. platys. This organism causes canine infectious cyclic thrombocytopenia which in most cases results in only mild illness if any. The owners reported prior tick bite (and tick paralysis) in this dog, but information on the identity of ticks on this dog (other than I. holocyclus) was not available. The absence of positive antibody results to A. platys in dogs in Group 4 was, however, unexpected since these dogs were regularly bitten by R. sanguineus, and the prevalence of this pathogen in rural Indigenous communities has been reported previously to be as high as 32% [28]. The absence of heartworm (D. immitis) antigen in any of the dogs tested is interesting and is in line with recent unpublished reports of an overall decrease in prevalence throughout Australia as a result of high uptake of heartworm prophylaxis medication [29].

In contrast to the rapid EIA results, approximately 23% of the dogs tested in this study were weakly positive (between 100 and 299.9 units) using the kinetic ELISA (KELA) with a solid phase antigenic substrate derived from whole, cultured B. burgdorferi (s.s) organisms. This ELISA is a sensitive test yet has poor specificity especially for equivocal canine serum samples (100–200 KELA units) [18]. The possible explanations for a positive result in this assay include exposure to the B. burgdorferi (s.l) genogroup; exposure to another Borrelia species (or group), either introduced or endemic to Australia; or cross-reactivity with antigens from other bacteria of unknown identity. The latter two explanations represent false positive results. As noted above, the absence of any sample testing positive for the C6 antigen strongly mitigates against the exposure to Bbsl in the dogs tested and furthermore, the absence of specific band patterns in the LIA results also reduces the likelihood of Bbsl exposure in this cohort. We believe another reason must be considered to explain this result.

Other Borrelia species are known to exist in Australia (reviewed in [12]). Two species of the genus Borrelia, B. theileri and B. anserina (relapsing fever spirochetes), were introduced to the continent by cattle and poultry,
respectively, and their vector ticks, during the establishment and development of the Australian agricultural industry since European settlement in 1788. Despite this, borreliosis in the form of relapsing fever in these domesticated animals is seldom diagnosed in Australia and is of relatively little economic impact. The species neither belong to the B. burgdorferi (s.l.) (Bbsl) complex (responsible for LB) nor (of more relevance with regard to serological testing) do the ticks responsible for their transmission, R. (Boophilus) australis and Argas persicus, respectively, bite people or dogs with any great frequency [22]. Questions about the presence of native Borrelia species, endemic to the Australian continent and therefore (presumably) maintained in sylvatic life-cycles, are largely unanswered at the present time. Spirochaetes were reported in marsupials and native rodents [30, 31] long before any molecular testing was available to reliably identify them, and the vectors of these organisms (if any) are unknown. Very recently DNA of novel Borrelia spp. has been amplified from a single I. holocyclus tick and from 39% Bothriocroton concor tick specimens (n = 97) feeding on echidnas (Tachyglossus aculeatus), a monotreme, in eastern Australia [32, 33]. Phylogenetic analysis has revealed this Borrelia species to exist in its own clade, distinct from the LB, Relapsing Fever and Reptile-associated Borrelia clades, and possibly represents a grouping that is unique to Australia. Nothing is known yet about its biology or whether it can be transmitted to other animals, including humans, but this seems unlikely given that B. concor is a specialist tick that feeds only from echidnas [22]. Next generation DNA sequencing of large numbers of I. holocyclus removed from a wide variety of hosts has, to date, failed to detect any more individual ticks infected with this organism [32, 34]. It seems unlikely therefore that the positive results in the kinetic ELISA test are due to an as yet unidentified Borrelia species in Australia.

It is intriguing that the prevalence of KELA seropositivity was higher in dogs with the greatest tick exposure (Groups 3 and 4) and that there was a significant association between seropositivity and tick paralysis, with foxhounds (Group 3) 2.7 times more likely to be seropositive than the dogs in Groups 1 and 2, suggesting a strong relationship between seropositivity and a clinically significant association with I. holocyclus. The interval between tick attachment and the development of neurological signs seems to be variable between individuals (and was actually absent in the foxhounds due to their tolerance of the venom) but generally develops between 4 and 5 days after attachment [35]. Regardless, it is plausible that infectious organisms, a potential source for cross-reacting antibodies in our ELISA, may be transmitted from the salivary glands (or midgut) at the same time that venom is injected once the tick is attached to the host. The possible identity of these infectious organisms remains unknown at the present time and is a subject that requires urgent investigation due to its potential to mislead diagnosis. One of the most contentious issues pertaining to the current LB debate in Australia pertains to the detection of antibodies against Borrelia spp. (and other pathogens including Anaplasma spp., Ehrlichia spp. and Babesia spp., for example) by laboratories testing serum from people who have never travelled outside Australia. We have conducted similar testing protocols in this study, applied to dogs and utilizing antigens and serological tests that have been developed for known pathogens in the northern hemisphere. Our interpretation of our dogs’ serology, based largely on the absence of reactivity to the C6 antigen and the absence of robust bands by line immunoassay, is that (1) the seroreactivity in nearly a quarter of the dogs tested, especially in those with tick exposure, represents cross-reactivity with antigens of as yet unidentified microorganism(s), (2) LB is an inappropriate diagnosis to make, and (3) appropriate diagnostic tools need to be applied. Furthermore, the microorganism(s) responsible for engendering this antibody response do not appear to be confined to I. holocyclus since our control group (Group 4), ostensibly included as a group with no possible exposure to paralysis ticks, yet with high tick exposure (to R. sanguineus), also returned positive results in 30% individuals.

**Conclusions**

We conclude that vector-borne infections with the pathogens tested in this study were extremely uncommon. Except for a single dog presumed to have been exposed to Anaplasma platys, infection with Anaplasma spp. Borrelia burgdorferi (s.l.), Ehrlichia spp. and Dirofilaria immitis, was not detected. We, therefore, propose that these results provide further evidence that Lyme borreliosis does not exist in Australia but that cross-reacting antibodies (false positive results), as determined in this study by KELA unit value > 100, are common and may be caused by the transmission of other tick-associated organisms.

**Abbreviations**

ANOVA: Analysis of variance; CI: Confidence interval; EDTA: Ethylenediaminetetraacetic acid; EIA: Enzyme immunoassay; KELA: Kinetic enzyme-linked immunosorbent assay; LB: Lyme borreliosis; LD: Lyme disease; LIA: Line immunoassay; NSW: New South Wales; OR: Odds ratio; PCR: Polymerase chain reaction; VlsE: vmp-like sequence E

**Acknowledgements**

The authors wish to acknowledge Sam Burke, Jenny Wingham, Amanda Paul, Clare Fisher, staff of Bayer Australia (Bob Rees, Brian Bean, Dan White, Christoph Vetten, and Warwick Smith) and Pittwater Council, and the veterinarians and nurses of the veterinary hospitals at Avalon, Bilgola, Mona Vale, Northern Beaches, Pittwater and St Ives, for assistance with blood collection and organisation of sample processing. We acknowledge and thank the Aboriginal elders in the west Kimberley region for permission to sample dogs at those Indigenous communities. In addition, we would like to thank Dr Ross Sillar (Northern Serums Pty Ltd) and Monika Biemacki (Monika’s Doggie Rescue), for
permission to sample their dogs. We also acknowledge Sharon Curtis and Idexx Laboratories Pty Ltd (Rydalmere, NSW 2116) for the generous donation of SNAP 4Dx kits for this study. Furthermore, we thank Elisabeth Aschinger for excellent technical assistance and Winston Yang for the preparation of the figure. This paper has been sponsored by Bayer Animal Health in the framework of the 12th CVBD World Forum Symposium.

Funding
This research did not receive external funding. SNAP 4Dx kits were kindly provided by Idexx Laboratories Pty Ltd (Rydalmere, NSW 2116).

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article. The raw data used and/or analysed during this study are available from the corresponding author on reasonable request.

Authors’ contributions
PJ conceived, designed and coordinated the study, collected samples, conducted EIA testing, collated and analysed the data, and wrote the manuscript; IDR conducted the statistical analysis and contributed to the manuscript; MEW and MP collected blood samples, conducted EIA testing, assisted in the coordination of the study and contributed to preparation of the manuscript; RKS contributed to the design of the study, conducted the serological testing in Germany, and assisted in writing the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare they have no competing interests.

Consent for publication
Not applicable.

Ethics approval
The study was approved by Human and Animal Research Ethics Committees at Murdoch University (approval numbers 2011/05 & R2385/10, respectively). Owners of animals tested consented to de-identified data being used for publication.

Author details
1 Vector and Water-Borne Pathogen Research Group, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia 6150, Australia. 2 College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia 6150, Australia. 3 Sydney School of Veterinary Science, University of Sydney, Sydney, New South Wales 2006, Australia. 4 Pymble Veterinary Clinic, Philip Mall, Kendall Street, West Pymble, New South Wales 2073, Australia. 5 Department of Infectious Diseases and Zoonoses, Bacteriology and Mycology, Ludwig-Maximilians-University Munich, 80539 Munich, Germany.

Received: 18 January 2017 Accepted: 23 February 2017
Published online: 13 March 2017

References
1. Goossens HAT, van den Berga A, Nohmann MKE. Dogs as sentinels for human Lyme borreliosis in The Netherlands. J Clin Microbiol. 2001;39:884–8.
2. Stone EG, Lacombe EH, Rand PW. Antibody testing and Lyme disease risk. Emerg Infect Dis. 2005;11:722–4.
3. Rand PW, Lacombe EH, Elias SP, Cahill BK, Lubelczyk CB, Smith RP. Multitarget test for emerging Lyme disease and anaplasmosis in a sera survey of dogs, Maine, USA. Emerg Infect Dis. 2011;17:899–902.
4. Smith FD, Ballantyne R, Morgan ER, Wall R. Estimating Lyme disease risk using pet dogs as sentinels. Comp Immunol Microbiol Infect Dis. 2012;35:163–7.
5. Wagner B, Erb HN. Dogs and horses with antibodies to outer-surface protein C as on-time sentinels for ticks infected with Borrelia burgdorferi in New York State in 2011. Prev Vet Med. 2012;107:275–9.
6. Eng TR, Wilson NL, Spielman A, Lastavica CC. Greater risk of Borrelia burgdorferi infection in dogs than in people. J Infect Dis. 1988;158:1410–1.
7. Duncan AW, Corea MT, Levine JF, Breitschwerdt EB. The dog as a sentinel for human infection: Prevalence of Borrelia burgdorferi C6 antibodies in dogs from Southeastern and Mid-Atlantic States. Vector Borne Zoonotic Dis. 2004;4:221–9.
8. Krupka I, Panchev N, Lorentzen L, Weise M, Straubinger RK. Tick-transmitted, bacterial infections in dogs: Serovar distribution of Anaplasma phagocytophilum, Borrelia burgdorferi sensu lato and Ehrlichia canis in Germany. Prakt Tierarzt. 2007;88:76–86.
9. Summers BA, Straubinger AF, Jacobson RH, Chang YF, Appel MJG, Straubinger RK. Histopathological studies of experimental Lyme disease in the dog. J Comp Path. 2005;131:1–13.
10. Mead P, Goel R, Kugeler K. Canine serology as adjunct to human Lyme disease surveillance. Emerg Infect Dis. 2011;17:1710–2.
11. Beaman MH. Lyme disease: Why the controversy? Intern Med J. 2016;46:1370–5.
12. Chalada MJ, Stenos J, Bradbury RS. Is there Lyme-like disease in Australia? Summary of the findings to date. One Health. 2016;2:42–54.
13. Collignon PJ, Lum GD, Robson JMB. Does Lyme disease exist in Australia? Med J Aus. 2016;205:413–17.
14. Australian Senate. Growing evidence of an emerging tick-borne disease that causes a Lyme-like illness for many Australian patients: Final Report. Canberra: 2016. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Lymeillness45/Final_Report. Accessed 14 Jan 2017.
15. Piesman J, Stone BF. Vector competence of the Australian paralysis tick, Ixodes holoclymenus, for the Lyme disease spirochete Borrelia burgdorferi. Int J Parasitol. 1991;21:109–11.
16. Baldock FC, Yamane I, Gardner I. Pilot survey for Lyme disease antibodies in Brisbane dogs. Aust Vet J. 1993;70:356–7.
17. Diagnostic Testing Laboratory, North Carolina State University: https://cmrncsu. clemson.edu/research/labs/clinical-sciences/vector-borne-disease. Accessed 16 Dec 2016.
18. Shin SJ, Chang Y-F, Jacobson RH, Shaw E, Lauderdale T-L, Appel MJG, Lein DH. Cross-reactivity between B. burgdorferi and other spirochetes affects specificity of serotests for detection of antibodies to the Lyme disease agent in dogs. Vet Microbiol. 1993;36:161–74.
19. Barth C, Straubinger RK, Krupka I, Mueller E, Sauter-Louis C, Hartmann K. Comparison of different diagnostic assays for the detection of Borrelia burgdorferi-specific antibodies in dogs. Vet Clin Path. 2014;43:496–504.
20. Halliday JEB, Meredith AL, Knobel DL, Shaw DJ, Bronsvoot BM, Cleveland S. A framework for evaluating animals as sentinels for infectious disease surveillance. J R Soc Interface. 2007;4:793–84.
21. Kiewra D, Lonc E. Epidemiological consequences of host specificity of tick (Ixodida). Ann Parasitol. 2012;58:181–7.
22. Roberts FHS. Australian ticks. Melbourne: Commonwealth Scientific and Industrial Research Organisation (CSIRO); 1970.
23. Toepfer KH, Straubinger RK. Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent - A study with five commercial vaccines using two different vaccination schedules. Vaccine. 2007;25:314–26.
24. Gerber B, Haug K, Eichenberger S, Reusch CE, Wittenbrink MM. Comparison of a rapid immunooassay for antibodies to the C6 antigen with conventional tests for antibodies to Borrelia burgdorferi in dogs in Europe. Vet Rec. 2006;166:354–7.
25. Hii SF, Traub RJ, Thompson MF, Henning J, O’Leary CA, Burleigh A, et al. Canine tick-borne pathogens and associated risk factors in dogs presenting with and without clinical signs consistent with tick-borne diseases in northern Australia. Aust Vet J. 2015;93:558–66.
26. Greay TL, Oksan CL, Gofton AW, Rees RL, Ryan UM, Irwin PJ. A survey of ticks (Acari: Ixodidae) of companion animals in Australia. Parasit Vectors. 2016;9:207.
27. Department of Agriculture and Water Resources, Australian Government. http://www.agriculture.gov.au/cats-dogs. Accessed 19 Dec 2016.
28. Brown GK, Canfield PJ, Dunstan RH, Roberts TK, Martin AR, Brown CS, et al. Detection of Anaplasma phagocytophilum and Babesia species in ticks on companion animals and associated risk factors. J Med J Aust. 2016;205:354–7.
29. Mitchell S. A cross-sectional serological survey of shelter cats and dogs in Australia to assess the prevalence of exposure to, and infection with Dirofilaria immitis. In: Australian Veterinary Association Conference Proceedings. 2012. http://ava2012.proceedings.com.au/files/papers/Mon% 20%20MITCHELL.pdf. Accessed 15 Jan 2017.
30. Pope J, Carly J. Isolation of Borrelia in native rats in north-west Queensland. Aust J Sci. 1956;19:1114.
33. Loh SM, Gofton AW, Lo N, Gillett A, Ryan U, Irwin P, et al. Novel Borrelia species detected in echidna ticks, Bothriocroton concolor, in Australia. Parasit Vectors. 2016;9:339.

34. Gofton AW, Doggett S, Ratchford A, Oskam CL, Paparini A, Ryan U, et al. Bacterial profiling reveals novel "Ca. Neoehrlichia", Ehrlichia, and Anaplasma species in Australian human-biting ticks. PLoS One. 2015;10:12.

35. Clunies-Ross I. Tick paralysis in the dog: period elapsing between attachment of tick and the onset of symptoms. Aust Vet J. 1934;10:182–3.